Background {#Sec1}
==========

Upper Gastrointestinal Bleeding is defined as hemorrhage originating from anywhere between the esophagus and the ligament of Treitz \[[@CR1]\]. It is one of the most common gastrointestinal emergencies, with an average mortality rate of 10% \[[@CR2], [@CR3]\]. Despite advances in the diagnosis and management of UGIB, the mortality rate has not changed significantly in the last 50 years \[[@CR2]--[@CR4]\].

Effective management requires use of a risk-stratification tool to categorise patients into low-risk and high-risk group, which can be used to guide treatment and follow up \[[@CR3]\].

Many risk factors for mortality have been found from different studies. A number of risk scores have been developed also. The most frequently used risk scoring system is the Rockall score which was developed in 1996. This score assesses the risk of death following UGIB and incorporates the patient's age, systolic blood pressure, heart rate, presence of other comorbidities and endoscopic findings \[[@CR3]\]. Another frequently used scoring system is the Glasgow Blatchford Score \[[@CR3]\].

Upper GI bleeding continues to be a significant cause of morbidity and mortality in Tanzania. For example, a one restrospective study enrolled 130 admitted patients with UGIB within two years \[[@CR5]\]. Similarly, in another study in northern Tanzania, of all patients who underwent a fiberoptic upper GI endoscopy, 18.7% were found to have evidence of UGIB \[[@CR6]\]. Oesophageal varices and peptic ulcer disease (PUD) being the most common causes in both these studies. Studies in Tanzania have shown a mortality rate ranging between 10 and 17% of patients admitted with UGIB \[[@CR5]--[@CR7]\].

This study was done at Muhimbili National Hospital (MNH) in Tanzania, which is the largest tertiary referral hospital currently in the country. No such studies had previously been done from this setting. Only one study was found that was prospectively done to find the risk factors of mortality among patients with UGIB. This study was aimed at identifying the causes of UGIB and risk factors for mortality in these patients, which would help better risk-stratify patients and guide management more efficiently, particularly in resource limited areas.

Methods {#Sec2}
=======

This was a prospective, cohort study where participants were recruited consecutively on admission from June 2015 to January 2016 and followed up for 60 days from admission.

The study population were all patients admitted to MNH due to UGIB. MNH is one of the four tertiary hospitals in the country. It also serves as a tertiary level referral for three municipal hospitals in Dar es Salaam. MNH admits patients with upper gastrointestinal bleeding primarily at Mwaisela Ward, which serves as the Internal Medicine ward for the hospital. The hospital receives approximately 25 to 30 patients a month with acute upper gastrointestinal bleeding. The patients are initially seen at the Emergency Medicine Department of the hospital and are then shifted to the medical ward after stabilization, where they are then managed accordingly. Facility for upper gastrointestinal endoscopy is available during official work hours and is performed by trained endoscopists in the department of Gastroenterology.

A target sample size of 100 patients was established based on sample size calculation with a confidence interval of 95%, a 5% margin of error and expected incidence of 10% \[[@CR7]\].

Data collection process {#Sec3}
-----------------------

All patients were entered into the study after an informed consent. Relevant data on demographics, medical history and comorbidities was collected on admission by interviewing the study participants or their guardians if the study participants were not able to answer. Admission vital signs from the Emergency Medicine Department (blood pressure, pulse rate, respiratory rate and oxygen saturation) were also recorded. Data on comorbidities was either confirmed by the patients themselves or through their records. Blood samples for laboratory tests were collected within 24 h of admission. Upper GI endoscopy was also done by trained personnel in the Gastroenterology Unit for those who could afford to pay for it in order to identify the cause and severity of the bleeding. (Approximately \$60).

All patients were then followed up while admitted in the ward, thereafter two-weekly follow-up was done after discharge up to 60 days post-initial admission or death.

UGIB was defined as any acute episode of vomiting blood or passing melena stool in the 24 h prior to admission to the hospital.

Rebleeding was defined as a separate episode of vomiting of fresh blood or melena, or nasogastric evidence of new bleeding after admission within the hospital or within 60 days post-admission.

Encephalopathy was defined as having symptoms and signs consistent with central nervous system involvement.

Chronic liver disease was defined by clinical criteria of stigmata of chronic liver disease with evidence of small liver span by clinical examination or ultrasound.

Renal insufficiency was defined as having acute kidney injury and/or chronic kidney disease from any cause.

All patients were treated according to standard treatment protocols of the hospital.

Data was analyzed using SPSS 23 for analysis. Relevant frequencies and tables were generated for all variables. Proportions and medians/interquartile ranges were calculated for appropriate variables. The differences in median values of continuous variables between the outcome groups was determined statistically by use of Mann-Whitney U test. Incidence of mortality, rebleeding and readmission were calculated. All risk factors were analyzed to determine their association with mortality by use of the chi-square test. Relative Risk was used as a measure of association for factors associated with 60-day mortality. Cox-regression analysis was done to find out the independent risk of each categorical variable towards 60-day mortality. All factors with a *p* value of \<0.05 in the bivariate analysis were included in the regression model. Missing indicator variable method was used to retain cases with missing data in the regression model. Statistical significance was set at *p* value \<0.05.

Results {#Sec4}
=======

Etiology of upper GI bleeding {#Sec5}
-----------------------------

From the 170 study participants, 86 underwent endoscopy. The most common cause of UGIB in these patients was oesophageal varices (57.0%), followed by peptic ulcer disease (18.6%) and gastritis (10.4%) (See Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Endoscopic etiologies of UGIB among 86 patients who underwent endoscopy

Patients who did not undergo endoscopy were more likely to have renal insufficiency (OR 3.30, 95% CI 1.31--8.33, p 0.009) and encephalopathy (OR 4.17, 95% CI 1.12--15.53, p 0.023) on admission. None of the patients with HIV infection underwent endoscopy (p 0.006).

Outcomes {#Sec6}
--------

Over a period of 60 days, 57 patients died (33.5%). Almost a quarter (24.6%) died in the first 24 h after admission, and almost half (49.1%) died within 72 h of admissions. Majority (96.5%) died in the first 30 days post-admission.

Rebleeding was present in 12 patients (7.1%). A quarter (25.0%) rebled within the first 96 h of admission.

Four patients were readmitted due to UGIB in the follow up period. All of them were readmitted after 30 days and before 60 days post-admission.

Figures [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"} show the Kaplan-Meier survival curves for the independent predictors of 60-day mortality. (See Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}).Fig. 2Kaplan-Meier Survival Curve for 60-day mortality by Serum Total Bilirubin Levels Fig. 3Kaplan-Meier Survival Curve for 60-day mortality by Serum ALT Levels Fig. 4Kaplan-Meier Survival Curve for 60-day mortality by WBC Count Fig. 5Kaplan-Meier Survival Curve for 60-day mortality by Endoscopy Status

Patient population is described in Table [1](#Tab1){ref-type="table"}. The association of mortality to different continuous variables (Table [2](#Tab2){ref-type="table"}) and categorical variables (Table [3](#Tab3){ref-type="table"}) revealed multiple significant associations. Factors that were significantly associated with mortality in univariate analysis (p \< 0.05) were entered into the regression model for multivariate analysis as shown in Table [4](#Tab4){ref-type="table"}.Table 1Clinical and Demographic Characteristics of Study PopulationCharacteristicMedian (25--75) / FrequencyAge40.0 (31.0--56.3)Sex Male121 (71.2%) Female49 (28.8%)History of previous UGIB65 (38.2%)Use of NSAIDs in previous one week7 (4.1%)Comorbidity Any Comorbidity106 (62.4%) Cardiac Disease14 (8.2%) Renal Insufficiency26 (15.3%) Chronic Liver Disease52 (30.6%) Encephalopathy14 (8.2%) Malignancy16 (9.4%) Hypertension13 (7.6%) Diabetes Mellitus5 (2.9%) HIV7 (4.1%)Smoking9 (5.3%)Alcohol use in previous one week22 (12.9%)Initial Vital Signs Systolic Blood Pressure (mmHg)113.5 (102.0--130.0) Diastolic Blood Pressure (mmHg)63.0 (56.8--80.3) Pulse Rate (beats/min)101.5 (86.0--108.3) Respiratory Rate (breaths/min)20.0 (19.0--23.0) Arterial Oxygen Saturation (%)100.0 (100.0--100.0)Initial Laboratory Data White Blood Count (k/μl)8.1 (4.6--12.4) Hemoglobin (g/dL)6.2 (4.5--8.8) Platelets (k/μl)178.5 (90.8--293.3) Serum Creatinine (μmol/L)78.0 (63.5--150.5) Serum BUN (g/dL)6.5 (3.3--12.6) Serum ALT (U/L)23.0 (15.0--47.0) Serum AST (U/L)36.0 (22.0--93.0) Serum Total Bilirubin (μmol/L)12.7 (7.6--29.9) Prothrombin Time (seconds)12.5 (11.2--14.1) APTT (seconds)28.4 (25.2--32.8) INR1.1 (1.0--1.3)Rockall Score Pre-Endoscopy3.0 (1.0--4.0) Post-Endoscopy6.0 (4.0--7.0)A total 170 individuals were recruited in the study. The mean and median age of the study population was 44.9 and 40.0 years, respectively. Majority were males (71.2%) and 38.2% had a previous episode of UGIB (either hematemesis or melena). Chronic liver disease was the most common comorbidity present (30.6%). (See Table [1](#Tab1){ref-type="table"}) Table 2Demographic and Clinical Predictors for 60-day Mortality (Continuous Variables)Factor60-day Mortality*p* valueYes\
(Median, 25--75)No\
(Median, 25--75)Age45.0 (33.5--57.5)39.0 (31.0--55.5)0.168Initial Vital Signs Systolic Blood Pressure (mmHg)114.0 (99.5--131.0)116.0 (103.0--130.0)0.513 Diastolic Blood Pressure (mmHg)70.0 (57.5--82.5)67.0 (56.0--79.0)0.419 Pulse Rate (beats/min)101.0 (91.0--113.0)97.0 (83.5--108.0)0.066 Respiratory Rate (breaths/min)20.0 (19.0--23.0)20.0 (19.5--23.0)0.972 Arterial Oxygen Saturation (%)100.0 (100.0--100.0)100.0 (100.0--100.0)*0.035*Initial Laboratory Data White Blood Count (k/μl)10.9 (7.7--16.7)6.7 (4.0--10.2)*\<0.001* Hemoglobin (g/dL)7.4 (4.9--9.3)6.0 (4.4--8.2)0.058 Platelets (k/μl)183.0 (133.0--278.0)172.5 (77.4--300.3)0.339 Serum Creatinine (μmol/L)105.5 (72.3--289.2)69.4 (62.2--101.6)*0.001* Serum BUN (g/dL)9.7 (4.7--23.4)4.5 (3.0--9.1)*0.001* Serum ALT (U/L)58.0 (14.3--113.0)21.0 (15.0--35.0)*0.004* Serum AST (U/L)74.0 (33.5--274.0)29.5 (18.0--50.8)*\<0.001* Serum Total Bilirubin (μmol/L)83.5 (17.7--421.1)11.3 (7.0--17.6)*0.001* Prothrombin Time (seconds)14.1 (12.7--19.4)12.1 (11.0--13.3)*0.002* APTT (seconds)28.5 (24.9--37.5)28.4 (25.2--31.4)0.533 INR1.3 (1.2--1.7)1.1 (1.0--1.2)*0.001*Rockall Score Pre-Endoscopy Rockall Score3.0 (2.0--4.0)3.0 (1.0--4.0)0.143 Post-Endoscopy Rockall Score6.0 (5.0--7.0)6.0 (4.0--7.0)0.620Comparison of medians of different continuous variables revealed that the following were all associated with a higher risk of mortality: A raised WBC, serum creatinine, serum BUN, serum ALT, serum AST, serum total bilirubin, prothrombin time and INR and reduced oxygen saturation on admission (*p* \< 0.05). (See Table [2](#Tab2){ref-type="table"}) Table 3Demographic and Clinical Predictors for 60-day Mortality (Categorical Variables)Factor60-day MortalityRelative Risk\
(95% CI)*P* valueYesNoTotalAge  \> 40 years31 (37.3%)52 (62.7%)831.250.303  ≤ 40 years26 (29.9%)61 (70.1%)87(0.82--1.91)Sex Male41 (33.9%)80 (66.1%)1211.040.878 Female16 (32.7%)33 (67.3%)49(0.65--1.67)History of previous UGIB Yes21 (27.6%)55 (72.4%)760.720.143 No36 (38.3%)58 (61.7%)94(0.46--1.13)Use of NSAIDs in previous one week Yes1 (14.3%)6 (85.7%)70.420.426 No56 (34.4%)107 (65.6%)163(0.07--2.58)Any Comorbidity Yes40 (37.7%)66 (62.3%)1061.420.135 No17 (26.6%)47 (73.4%)64(0.88--2.29)Cardiac Disease Yes6 (42.9%)8 (57.1%)141.310.556 No51 (32.7%)105 (67.3%)156(0.69--2.50)Renal Insufficiency Yes16 (61.5%)10 (38.5%)26*2.160.001* No41 (28.5%)103 (71.5%)144*(1.45--3.22)*Chronic Liver Disease Yes21 (28.0%)54 (72.0%)750.740.175 No36 (37.9%)59 (62.1%)95(0.47--1.15)Encephalopathy Yes11 (78.6%)3 (21.4%)14*2.67\<0.001* No46 (29.5%)110 (70.5%)156*(1.85--3.84)*Malignancy Yes9 (56.3%)7 (43.8%)16*1.810.043* No48 (31.2%)106 (68.8%)154*(1.1--2.95)*Hypertension Yes6 (46.2%)7 (53.8%)131.420.364 No51 (32.5%)106 (67.5%)157(0.76--2.67)Diabetes Mellitus Yes4 (80.0%)1 (20.0%)5*2.490.044* No53 (32.1%)112 (67.9%)165*(1.52--4.07)*HIV Yes5 (71.4%)2 (28.6%)7*2.240.043* No52 (31.9%)111 (68.1%)163*(1.33--3.76)*Smoking Yes3 (33.3%)6 (66.7%)90.991.000 No54 (33.5%)107 (66.5%)161(0.39--2.57)Alcohol use in previous one week Yes8 (36.4%)14 (63.6%)221.100.763 No49 (33.1%)99 (66.9%)148(0.60--2.00)Systolic Blood Pressure  \< 110 mmHg23 (37.1%)39 (62.9%)621.180.455  ≥ 110 mmHg34 (31.5%)74 (68.5%)108(0.77--1.81)Diastolic Blood Pressure  \< 60 mmHg17 (31.5%)37 (68.5%)540.910.700  ≥ 60 mmHg40 (34.5%)76 (65.5%)116(0.57--1.46)Pulse Rate  \> 100 bpm30 (38.5%)48 (61.5%)781.310.210  ≤ 100 bpm27 (29.3%)65 (70.7%)92(0.86--2.00)Respiratory Rate  \> 18 bpm44 (32.6%)91 (67.4%)1350.880.611  ≤ 18 bpm13 (37.1%)22 (62.9%)35(0.54--1.44)Arterial Oxygen Saturation  \< 92%2 (50.0%)2 (50.0%)41.510.603  ≥ 92%55 (33.1%)111 (66.9%)166(0.55--4.12)White Blood Count (k/μl)  \> 11.0026 (54.2%)22 (45.8%)48*2.23\<0.001*  ≤ 11.0028 (24.3%)87 (75.7%)115*(1.47--3.37)*Hemoglobin (g/dL)  \< 10.0045 (31.7%)97 (68.3%)1420.740.310  ≥ 10.009 (42.9%)12 (57.1%)21(0.43--1.28)Platelets (k/μl)  \< 14018 (26.5%)50 (73.5%)680.690.115  ≥ 14036 (38.3%)58 (61.7%)94(0.43--1.11)Serum Creatinine (μmol/L)  \> 11521 (53.8%)18 (46.2%)39*2.200.001*  ≤ 11522 (24.4%)68 (75.6%)90*(1.38--3.51)*Serum BUN (g/dL)  \> 7.421 (47.7%)23 (52.3%)44*2.390.003*  ≤ 7.412 (20.0%)48 (80.0%)60*(1.32--4.32)*Serum ALT (U/L)  \> 5517 (73.9%)6 (26.1%)23*4.19\<0.001*  ≤ 5515 (17.6%)70 (82.4%)85*(2.49--7.04)*Serum AST (U/L)  \> 3424 (40.7%)35 (59.3%)59*2.350.007*  ≤ 349 (17.3%)43 (82.7%)52*(1.20--4.59)*Serum Total Bilirubin (μmol/L)  \> 20.513 (50.0%)13 (50.0%)26*5.00\<0.001*  ≤ 20.55 (10.0%)45 (90.0%)50*(2.0--12.50)*Prothrombin Time (seconds)  \> 12.113 (46.4%)15 (53.6%)28*3.710.008*  ≤ 12.13 (12.5%)21 (87.5%)24*(1.20--11.51)*APTT (seconds)  \> 30.47 (35.0%)13 (65.0%)201.080.842  ≤ 30.411 (32.4%)23 (67.6%)34(0.50--2.34)INR  \> 1.1313 (48.1%)14 (51.9%)27*4.170.004*  ≤ 1.133 (11.5%)23 (88.5%)26*(1.34--12.97)*Endoscopy Not Done46 (54.8%)38 (45.2%)84*4.28\<0.001* Done11 (12.8%)75 (87.2%)86*(2.39--7.69)*Endoscopy Diagnosis Oesophageal Varices6 (12.2%)43 (87.8%)490.911.000 Other Diagnosis5 (13.5%)32 (86.5%)37(0.30--2.74)Pre-Endoscopy Rockall Score1.29  \> 321 (39.6%)32 (60.4%)53(0.84--1.98)0.257  ≤ 336 (30.8%)81 (69.2%)117Post-Endoscopy Rockall Score  \> 58 (15.1%)45 (84.9%)531.610.524  ≤ 53 (9.4%)29 (90.6%)32(0.46--5.63)Mortality was also compared to different categorical variables as outlined in Table 3. A high serum total bilirubin was associated with a 5-fold increased risk of mortality (RR = 5.00, *p* \< 0.001). Patients with a raised serum ALT level (RR = 4.19, *p* \< 0.001), a raised INR (RR = 4.17, *p* = 0.004), a prolonged prothrombin time (RR = 3.71, *p* = 0.008) and those who did not undergo endoscopy during admission (RR = 4.28, *p* \< 0.001) had an almost 4-fold increased risk of mortality within 60 days from admission. Other factors that were associated with a higher risk of mortality included patients with renal insufficiency (RR = 2.16, *p* \< 0.001), encephalopathy (RR = 2.67, *p* \< 0.001), malignancy (RR = 1.81, *p* = 0.043), diabetes mellitus (RR = 2.49, *p* = 0.044), HIV disease (RR = 2.24, *p* = 0.043), a raised WBC count (RR = 2.23, *p* \< 0.001), a raised serum creatinine level (RR = 2.20, *p* = 0.001), a raised serum BUN level (RR = 2.39, *p* = 0.003), and a raised serum AST level (RR = 2.35, *p* = 0.007). (See Table [3](#Tab3){ref-type="table"}) Table 4Cox-Regression Analysis of Predictors for 60-day Mortality (Multivariate Analysis)PredictorHazard Ratio (95% CI)*P* valueRenal Insufficiency1.38 (0.54--3.51)0.504Encephalopathy1.19 (0.46--3.06)0.723HIV0.58 (0.16--2.07)0.402Diabetes Mellitus2.14 (0.54--8.50)0.279Malignancy0.58 (0.21--1.64)0.303White Blood Cell Count \>11 k/μl*2.45 (1.23--4.89)0.011*Serum Creatinine \>115 μmol/L1.55 (0.57--4.23)0.896Serum BUN \>7.4 g/dL1.46 (0.55--3.85)0.445Serum ALT \>55 U/L*4.22 (1.31--13.57)0.016*Serum AST \> 34 U/L1.11 (0.39--3.17)0.843Serum Total Bilirubin \>20.5 μmol/L*5.79 (1.58--21.25)0.008*Prothrombin Time \> 12.1 s0.33 (0.01--21.14)0.598INR \> 1.138.57 (0.14--536.04)0.309Endoscopy Not Done*4.40 (2.11--9.17)\<0.001*Multivariate analysis to identify independent predictors of 60-day mortality was done using Cox-Regression analysis. Factors that were shown to be significantly associated with a higher risk of 60-day mortality by bivariate analysis were included in the regression model. Multivariate analysis showed that a higher WBC count of \>11 k/μl, a high serum ALT \>55 U/L, a high serum total bilirubin \>20.5 μmol/L were independently associated with an increased risk of mortality. Patients who did not undergo endoscopy had a 4.4 times higher rate of death within 60 days of admission (Table [4](#Tab4){ref-type="table"})

Discussion {#Sec7}
==========

This prospective, cohort study aimed at identifying the major causes of upper gastrointestinal bleeding and the magnitude of mortality, rebleeding and readmission and their risk factors in a tertiary level hospital in Tanzania.

The most common cause of upper GI bleeding in this study group was oesophageal varices, found in 57% of patients. PUD accounted for 18% of cases (equally distributed among duodenal and gastric ulcer). The high prevalence of oesophageal varices has also been found in studies done in other regions of Tanzania such as Moshi \[[@CR5]\] and Mwanza \[[@CR6], [@CR7]\]. In contrast, PUD was the most common cause of UGIB in studies done in Korea \[[@CR8]\], USA \[[@CR9]\] and various European countries \[[@CR3], [@CR10]\].

Oesophageal varices are most often a result of portal hypertension. Schistosomiasis and chronic liver disease are among the most common causes of portal hypertension in sub-Saharan Africa. The prevalence of chronic liver disease is similar to studies done in Romania \[[@CR3], [@CR4]\]. However, this prevalence is higher than those found in studies in Mwanza \[[@CR6], [@CR7]\], Europe \[[@CR11]\] and Korea \[[@CR8], [@CR12]\]. One reason for this could be the type of patients involved in this study. The study was conducted in a tertiary referral center, hence it admits patients with the most severe forms of disease. Secondly, although not directly tested, the high prevalence of schistosomiasis and chronic hepatitis B infection in this setting may have contributed to the high prevalence of chronic liver disease. More than 90% of cases of schistosomiasis occur in sub-Saharan Africa and Tanzania is the second highest in terms of burden of disease in this region \[13\]. The estimated country prevalence of schistosomiasis is 51.5% \[[@CR13]\]. One study done in Mwanza showed a high rate of active schistosome infection in adults presenting with hematemesis \[[@CR7]\]. Similarly, one study found a 12.4% positivity of *S. mansoni* in stool samples \[[@CR14]\] Studies in Tanzania have shown a prevalence of chronic hepatitis B infection ranging from 2.9--7.0% \[[@CR15]--[@CR17]\].

PUD was the second most common diagnosis. It is well known that PUD is associated with *H. pylori* infection*.* Studies done in Tanzania have shown a prevalence of *H. pylori* to be more than 85% in the population \[[@CR18]--[@CR20]\]. The prevalence was shown to increase with age \[[@CR19]\].

The overall mortality rate within 60 days of admission was 33.5%. This is very high compared to the overall mortality rate from upper GI bleeding worldwide \[[@CR2]\]. Many studies looking at mortality rates among patients with upper GI bleeding have shown mortality rates ranging from 1 to 20% \[[@CR3], [@CR6], [@CR7], [@CR9], [@CR21]--[@CR24]\]. A few studies have mortality rates higher than 30% \[[@CR10], [@CR25], [@CR26]\].

The high mortality rate in this study could be due to delayed or more severe presentation to a referral center, thus increasing the likelihood of mortality due to delay or failure in achieving hemodynamic stability, particularly in the absence of urgent endoscopic intervention. Furthermore, there is a general lack of available intervention measures such as blood transfusion and urgent endoscopic intervention and this may have contributed to the high mortality. It is noteworthy that almost half of the patients died within 72 h of admission to the hospital, suggesting the importance of early intervention as the key in the management of patients with acute UGIB.

A high WBC count was associated with almost 2.5 times higher rate of death compared to patients with a normal WBC count on admission. A high WBC has been associated with mortality in other studies too \[[@CR27]--[@CR29]\]. Leukocytosis is a marker for inflammation and infection, but it also occurs in other situations like trauma, exercise, drug therapy with steroids, malignancy, poisoning, psychosis and diabetic ketoacidosis. Circulating catecholamines may also lead to leukocytosis. It has been speculated that leukocytosis may represent an acute phase marker \[[@CR30]\]. One study on upper GI bleeding patients revealed that a high WBC count was associated with more severe presentation and disease course, although it was not associated with a higher risk of mortality. The authors used a lower cut-off value of high WBC (8.5 k/μl) \[[@CR31]\] Several studies have shown the association between leukocytosis and higher risk of mortality in various conditions \[[@CR32]--[@CR34]\]. It is possible that some underlying infection or inflammatory condition contributed to the mortality in these patients.

Patients admitted with elevated ALT had about 4 times higher rate of death within 60 days compared to patients admitted with normal levels of ALT. Abnormal liver enzymes, particularly a raised ALT has been shown to be a risk factor for mortality in different studies \[[@CR3], [@CR24], [@CR35], [@CR36]\].

ALT levels can be raised in patients with myocardial infarction and with ischemia to the liver \[[@CR37]\]. Although these were not measured directly, it is possible that more severe bleeding was associated with ischemia to the heart and liver, thus contributing to the higher mortality. Higher levels of ALT have also been associated with obesity, serum cholesterol and underlying unrecognized liver diseases \[[@CR37], [@CR38]\]. It may be possible that these comorbidities may have contributed to mortality in this group of patients.

A high serum total bilirubin during admission was associated with an almost 6 times increased rate of death in this study population. Other studies have also shown this association between high serum total bilirubin and mortality \[[@CR21], [@CR22], [@CR25], [@CR31], [@CR36], [@CR39], [@CR40]\]. High levels of serum total bilirubin have been associated with all-cause mortality \[[@CR41], [@CR42]\]. The exact mechanism is unclear. It has been shown in different studies that a high level of serum total bilirubin is associated with cardiovascular disease, particularly ischemic heart disease \[[@CR43]\] and acute myocardial infarction \[[@CR44]\]. The increased risk of acute cardiovascular events in patients with high serum total bilirubin may have contributed to the increased mortality rate in this study group.

Patients who did not undergo endoscopy during their hospital stay had about 4 times a higher rate of death within 60 days compared to patients who had an endoscopy done. Lack of endoscopy was shown to be a risk factor for mortality in another study done in Bugando \[[@CR7]\]. It may be possible that patients who were hemodynamically unstable and very sick overall on admission did not undergo endoscopy and were at higher risk of mortality, as seen by the fact that patients with renal insufficiency, HIV and encephalopathy were all less likely to undergo endoscopy. Consensus guidelines outline the importance of endoscopy in acute upper GI bleeding. It helps to identify the source of bleeding, provide prognostic information regarding the risk of bleeding, and offer therapy for hemostasis \[[@CR45]\]. One study also showed reduced incidence of myocardial infarction and overall mortality in patients who received initial resuscitation (including endoscopic intervention) \[[@CR46]\] Hence, the patients who did not undergo endoscopy may have missed the chance to be offered endoscopic intervention because of a lack of diagnosis and this may be the reason for the increased mortality rate in this group of patients.

The strength of this study was that it was a prospective study where many variables that could potentially predict adverse outcomes were assessed. Furthermore, all patients were followed-up in this study.

The study had some limitations. Half of the patients did not undergo endoscopy due to not being able to afford it. This may have underestimated the burden of some etiologies. Importantly, not undergoing endoscopy was an independent predictor of mortality. Therefore, more serious etiologies may have been missed which led to early death. Some laboratory values were not obtained for some patients and this may have underestimated or overestimated the significance of these factors with the outcomes. Presence of comorbidities was assessed by patient interview or clinical diagnosis. True melena was ascertained verbally only. This may have included some patients who had black stool from ingestion of previously prescribed ferrous sulphate. Gold standard criteria for diagnosis of comorbidities were not used in all patients. This study identified an important area in the local country but the results may not necessarily be generalisable to settings with different epidemiological disease patterns, particularly for chronic liver disease. Subgroup analysis to identify specific risk factors for mortality following variceal bleeding and ulcer bleeding could not be done due to small sample size these subgroups would have.

Conclusions {#Sec8}
===========

Oesophageal varices was the most common cause of UGIB, followed by peptic ulcer disease. There was a high burden of mortality in this study, about one-third of patients admitted with UGIB died within 60 days. Rebleeding and readmission rates were low. Independent predictors of 60-day mortality were a high WBC count, raised serum ALT, raised serum total bilirubin and a lack of endoscopy. It is recommended that patients require early and more aggressive intervention in acute UGIB and possibly larger studies can be conducted looking at other factors that may contribute to mortality in UGIB patients. It is also important to study the reasons for a lack of endoscopy among patients with UGIB since this is a potentially correctable factor which can then lead to reduction in mortality and improvement on clinical care of these patients in the country.
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